The World Health Organization has confirmed that the Ebola outbreak in the Democratic Republic of the Congo, caused by the Bundibugyo virus strain, is the largest in the country's history and the world's second-largest on record, with 3,605 confirmed cases and 1,587 deaths as of 30 July 2026 — a case fatality rate of 44 percent. BBC News; Al Jazeera

The outbreak was declared on 15 May 2026 in Ituri Province, which borders South Sudan and Uganda, and was elevated by WHO Director-General Tedros Adhanom Ghebreyesus to a Public Health Emergency of International Concern on 17 May 2026. At that point, eight laboratory-confirmed cases, 246 suspected cases, and 80 suspected deaths had been reported in Ituri alone. Confirmed cases were also identified in Uganda, prompting the PHEIC declaration to cover both countries. WHO

The trajectory since mid-May has been steep. Between 3 July and mid-July, WHO documented an additional 664 confirmed cases and 376 confirmed deaths. In the most recent reporting week, the outbreak reached its highest weekly total: 567 cases and 296 deaths. WHO stated on X that the outbreak was "intensifying, with sustained transmission and continued increases in reported cases and deaths," and warned that the weekly figures underscored "the exceptional pace of transmission." BBC News; WHO

The Guardian reported on 31 July that the outbreak is the fastest-growing in the history of the Ebola virus, with case numbers approaching the previous worst toll of the 2018–2020 outbreak in which 3,470 people were infected. That earlier eastern DRC outbreak, which also spread to Uganda, recorded 3,481 cases and 2,299 deaths, according to a 2024 WHO SAGE report — a case fatality rate of roughly 66 percent. The current outbreak has now surpassed it in confirmed case count, though the Bundibugyo strain's lower fatality rate means the death toll has not yet matched the earlier epidemic. The Guardian; WHO SAGE

The Bundibugyo strain is a critical variable in this outbreak. Unlike Zaire ebolavirus, for which the rVSV-ZEBOV vaccine demonstrated efficacy during the 2018–2020 epidemic, there is currently no approved vaccine or therapeutic for Bundibugyo. Vaccine candidates are under development in the United Kingdom and Singapore, but the absence of a licensed countermeasure means the response relies entirely on surveillance, contact tracing, isolation, and supportive care. The geographic context compounds the difficulty: the outbreak is centered in Ituri and has spread to North and South Kivu provinces, regions long affected by armed conflict, mass displacement, and porous borders with Uganda and South Sudan. WHO cited insecurity, population displacement, and cross-border movement as factors that "continue to hamper Ebola response efforts and increase the risk of further spread." BBC News

Ebola virus disease, which spreads through contact with bodily fluids, has killed approximately 15,000 people across Africa over the past 50 years. The 2014–2016 West African epidemic, centered in Guinea, Liberia, and Sierra Leone, remains the largest on record, though the current DRC outbreak is now the world's second-largest. A July 2015 WHO situation report from that earlier epidemic documented 26 confirmed cases in a single week (22 in Guinea, 4 in Sierra Leone), a pace the current outbreak has dwarfed more than twentyfold in its most recent reporting period. BBC News; WHO

Ministry of Public Health data compiled as of 31 July recorded 1,556 deaths at a case fatality rate of 44.1 percent, broadly consistent with the WHO's 30 July figures. The convergence of sources on a 44 percent fatality rate is notable: Bundibugyo ebolavirus historically carries a lower fatality rate than Zaire ebolavirus, which typically exceeds 60 percent. The lower lethality, combined with the absence of vaccination, creates conditions in which transmission can persist longer in communities because a greater share of infected individuals survive and remain mobile.

The operational challenge is substantial. The PHEIC declaration was intended to trigger coordinated international resource mobilization, but WHO's characterization of the outbreak as "intensifying" nearly three months later indicates that containment has not yet been achieved. The combination of an unvaccinable strain, active conflict zones, cross-border population movement, and a transmission pace WHO describes as "exceptional" places this outbreak in a category that the 2018–2020 response — despite its eventual success — did not fully face. The development of Bundibugyo vaccines in the UK and Singapore is a forward-looking effort, but the timeline for clinical validation, regulatory approval, and deployment under emergency use is measured in months at minimum. In the interim, the response's trajectory will be shaped by whether community engagement, contact tracing, and cross-border surveillance can keep pace with transmission that WHO has described as accelerating week over week.